Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First‑in‑Class Antibody Therapy for von Willebrand Disease

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced that its clinical trial program for VGA039 has been initiated. The first subject has been dosed in the Phase 1 study of VGA039 (NCT05776069), a multinational clinical trial being conducted following approvals of the Investigational New Drug Application (IND) by the U.S. Food and Drug Administration (FDA) and Clinical Trial Application (CTA) in Europe. The clinical trial program will begin with enrollment of healthy volunteers and expand to include patients with von Willebrand disease (VWD).

VGA039 is a first-in-class antibody therapy with a novel mechanism of action that modulates Protein S – a key co-factor involved in thrombin generation during both initiation and propagation of coagulation – with preclinical data demonstrating efficacy in numerous congenital bleeding disorders, including VWD. By promoting thrombin generation through targeting Protein S, VGA039 addresses a fundamental mechanism of clot formation in VWD and, as a subcutaneously self-administered antibody therapy, has potential to transform VWD treatment. VGA039 also has potential to treat additional bleeding disorders, including other factor deficiencies and platelet disorders.

“We are excited to advance VGA039 into the clinic as the first purpose-built antibody therapy for VWD, representing a new approach with the potential to reduce the treatment burden for these patients,” said Gary Patou, MD, Chief Medical Officer of Vega Therapeutics.

Click the button below to read the entire Press Release:

Continue Reading The Press Release